Grezegorz Nowakowski Md

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

Dr Nowakowski on the Current Treatment Landscape for DLBCL

Dr. Nowakowski on the Potential Role of Immunotherapy in MCL

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

Być dzieckiem Bożym - Grzegorz Nowakowski

Kościół Zielonoświątkowy Kraków Nowa Huta

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

Prof. Grzegorz Nowakowski | ASH 2017 | Time from diagnosis to treatment in DLBCL

Osądzać czy nie ? Grzegorz Nowakowski

Kościół Zielonoświątkowy Kraków Nowa Huta

Dr. Nowakowski on Evolving Treatment Paradigm of MCL

Dr. Nowakowski on Biological Heterogeneity in Newly Diagnosed Patients With MCL

"The HemOnc Pulse" Live: Dr. Nowakowski Reflects on the Hodgkin Lymphoma Panel

Blood Cancers Today

Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

Prof. Grzegorz Nowakowski | ASH 2017 | Update from diagnosis to treatment

Second-Line Therapy for CNS Lymphoma: How Do Experts Choose?

Blood Cancers Today

Dr. Nowakowski on Next Steps With Emerging Agents in MCL

Portret Jezusa - Grzegorz Nowakowski

Kościół Zielonoświątkowy Kraków Nowa Huta

Identifying high-risk DLBCL and optimizing treatment for these patients

VJHemOnc – Video Journal of Hematology & HemOnc

Greg Nowakowski | Gene expression profiling in ABC-type DLBCL patients: ROBUST phase III trial

Managing relapse post-CAR-T therapy in DLBCL & the need to change clinical trial inclusion criteria

VJHemOnc – Video Journal of Hematology & HemOnc